Axsome Therapeutics (AXSM) IPO Opens, Trades Flat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Axsome Therapeutics Announces Pricing of Initial Public Offering
November 19, 2015 11:39 AM ESTNEW YORK, Nov. 19, 2015 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system (CNS) disorders, today announced the pricing of its initial public offering of 5,666,667 shares of its common stock at a public offering price of $9.00 per share. Axsome Therapeutics has granted the underwriters a 30-day option to purchase up to an aggregate of 850,000 additional shares of common stock at the initial public offering price to cover any over-allotments. The shares are expected to begin trading on the NASDAQ Capital Market on November 19,... More
